Hypothesis

Combined pharmacological recoupling of eNOS and blockade of ICAM-1-mediated leukocyte adhesion will suppress the senescence-associated secretory phenotype (SASP) in endothelial cells more effectively than either intervention alone, breaking the ROS–NF-κB–ICAM-1 positive feedback loop.

Rationale

Endothelial senescence generates a self‑amplifying circuit: eNOS uncoupling produces superoxide that activates NF-κB, driving ICAM-1 transcription; ICAM-1‑dependent leukocyte adhesion adds extracellular ROS that further oxidizes BH4 and sustains eNOS uncoupling [1][2][3]. SASP cytokines such as IL-6 and IL-8 are upregulated downstream of NF-κB and MAPK signaling [4]. While BH4 supplementation restores eNOS coupling and anti‑ICAM-1 antibodies reduce leukocyte recruitment, each approach leaves one arm of the loop intact, allowing residual signaling to maintain SASP. Simultaneously targeting both nodes should collapse the loop, lower mitochondrial and NADPH oxidase ROS, diminish NF-κB nuclear translocation, and consequently attenuate SASP factor secretion.

Experimental Design

In vitro: Human umbilical vein endothelial cells (HUVECs) will be induced to senesce via low‑dose TNF‑α (10 ng/mL) for 5 days [3]. Four treatment groups will be tested: (1) vehicle, (2) BH4 (10 µM) to recouple eNOS, (3) anti‑ICAM‑1 blocking antibody (5 µg/mL), (4) BH4 + anti‑ICAM‑1. After 24 h of treatment, we will measure: superoxide production (DHE fluorescence), eNOS coupling (nitrate/nitrite ratio), NF-κB p65 nuclear translocation (immunofluorescence), ICAM-1 surface expression (flow cytometry), leukocyte adhesion (THP‑1 monocytes under shear), and SASP cytokines (IL‑6, IL‑8 ELISA).

In vivo: ApoE‑/‑ mice fed a Western diet for 12 weeks will receive either BH4 (via oral gavage, 2 mg/kg/day), anti‑ICAM‑1 antibody (i.p., 10 mg/kg twice weekly), both, or control for 4 weeks. Endothelial senescence will be assessed by SA‑β‑gal staining and p16^INK4a^ immunohistochemistry in aortic root sections. Aortic inflammation will be quantified by leukocyte infiltration (CD45+ ICAM-1+ cells), ROS (dihydroethidium), and plasma IL-6/IL-8 levels.

Expected Outcomes

If the hypothesis is correct, the combined BH4 + anti‑ICAM‑1 group will show: (i) the greatest reduction in eNOS‑derived superoxide and the highest NO bioavailability; (ii) the lowest NF-κB nuclear activity and ICAM-1 expression; (iii) markedly decreased leukocyte adhesion and transmigration; and (iv) a significant drop in IL-6 and IL-8 secretion compared with monotherapies or controls. In mice, combination treatment should yield the smallest senescent endothelial burden, lowest aortic ROS, and reduced plasma SASP cytokines, whereas single agents produce only partial improvements. Failure to observe additive or synergistic effects would falsify the hypothesis and suggest that additional pathways (e.g., mitochondrial DNA damage or inflammasome activation) sustain SASP independently of the eNOS‑ICAM-1 axis.

Novel Mechanistic Insight

We propose that leukocyte‑derived myeloperoxidase (MPO) released during adhesion amplifies eNOS uncoupling by oxidizing BH4 and generating tyrosine‑nitrated eNOS, a modification not fully reversed by BH4 alone. Simultaneous ICAM‑1 blockade prevents MPO delivery, allowing BH4 to fully recouple eNOS. This dual hit explains why targeting only one node leaves a residual oxidative source that preserves NF-κB signaling and SASP.

[1] https://digitalcommons.pcom.edu/cgi/viewcontent.cgi?article=1001&context=biomed [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC9996905/ [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC2544488/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC12106568/ [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC7174952/ [6] https://pmc.ncbi.nlm.nih.gov/articles/PMC7977775/ [7] https://pmc.ncbi.nlm.nih.gov/articles/PMC9898542/